|
News
:
BIOWIRE
CSMG Technologies, Inc., (OTCBB: CTUM) focused on commercializing human live tissue bonding devices and renewable energy landfill gas production systems, announced its Live Tissue Connect subsidiary will present a white paper at the European Society of Coloproctology (ESCP), a prestigious international surgical conference currently underway in Lisbon, Portugal, September 14-16.
Dr. Sergiy Podpriatov, a clinical researcher and practicing surgeon, will present a white paper on Live Tissue Connect's welding/bonding technology being utilized to more effectively connect tissue of individuals undergoing surgical procedures on the hemorrhoids. The paper being presented by Dr. Podpriatoy is titled "SUBMUCOSAL ELECTRIC WELDING OF THE COMPLICATED HEMORRHOIDS."
To view the poster of the paper being presented by Dr. Podpriatov,
please go to:
http://www.ctum.com/whitepapers.html
For further information on ESCP their website is www.escp.eu.com.
Donald S. Robbins, president and CEO of CSMG, said, "The paper being presented before the ESCP is indicative of the tremendous strides Live Tissue Connect is making to address the critical need of surgeons, and their patients, to have a highly effective, fast device that allows human tissue to be connected efficiently, without the use of sutures, glues, sealant or staples. Our devices have been used in more than 70 types of open and laparoscopic surgical procedures. We believe the global surgical and medical communities see the versatility of the tissue welding technology. Presentations before such professional societies continue to raise our visibility and credibility within important groups of healthcare professionals. We are continuing to develop our technology, and procedures."
About CSMG Technologies' Tissue Welding/Bonding Technology
Surgeons at 10 Ukraine hospitals and clinics are using the tissue welding/bonding technology in clinical trials. They have completed more than 6,000 human surgeries using more than 70 types of open and laparoscopic surgical procedures, demonstrating the technology is universal in its ability to repair soft biological tissue. These surgeries included lung, neuro-surgery, nasal septum, intestine, stomach, skin, gall bladder, liver, spleen, blood vessels, nerves, alba linea, uterus, bladder, gynecological, fallopian tube, ovary and testicles and dura-matter. Cosmetic surgeries conducted with this technology include breast reduction, breast implants, mastopexy and abdominal plasty. The procedure involves little or no scarring, while restoring the normal function of the body organ or tissue.
The technology was invented and developed at the internationally renowned E.O. Paton Institute of Electric Welding, National Academy of Sciences of Ukraine, Kiev, Ukraine, headed by Professor B.E. Paton. U.S. and Australia patents have been issued, a patent in the European Union has been approved, and additional U.S. and foreign patents are pending.
About CSMG Technologies, Inc.
CSMG Technologies is a technology management company that finances, owns, develops, licenses and markets innovative advanced technologies and business opportunities created in the Ukraine through a network of scientific institutes and private organizations. CSMG has three subsidiaries, Live Tissue Connect, Inc., CSMG Gastech, LLC and Anaerobic Farm Waste, Inc. For further information on CSMG Technologies and its various subsidiaries, please visit our website at www.ctum.com.
This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934 as amended (the Exchange Act), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the company, its directors or its officers with respect to, among other things: (i) the company's financing plans; (ii) trends affecting the company's financial condition or results of operations; (iii) the company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words ``may,'' ``would,'' ``will,'' ``expect,'' ``estimate,'' ``anticipate,'' ``believe,'' ``intend'' and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.
|
